Analysts' ratings for Lyra Therapeutics (NASDAQ:LYRA) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
2
0
0
Last 30D
0
0
2
0
0
1M Ago
1
0
0
0
0
2M Ago
2
0
0
0
0
3M Ago
0
0
0
0
0
Analysts have recently evaluated Lyra Therapeutics and provided 12-month price targets. The average target is $7.5, accompanied by a high estimate of $12.00 and a low estimate of $0.50. A decline of 31.82% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Lyra Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Matthew Caufield
HC Wainwright & Co.
Announces
Neutral
$2.00
-
Dennis Ding
Jefferies
Lowers
Hold
$0.50
$10.00
Matthew Caufield
HC Wainwright & Co.
Maintains
Buy
$12.00
-
Jason Gerberry
B of A Securities
Lowers
Buy
$11.00
$12.00
Matthew Caufield
HC Wainwright & Co.
Maintains
Buy
$12.00
-
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lyra Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: ...Full story available on Benzinga.com
Benzinga
